Cargando…
The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
PCSK9 inhibitors (PCSK9i) are monoclonal antibodies that have been shown to be effective in reducing both LDL cholesterol (LDL-C) values and major cardiovascular events in patients at high cardiovascular risk. Adherence to PCSK9i is critical for the success of the treatment. The aim of the present s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836402/ https://www.ncbi.nlm.nih.gov/pubmed/35159928 http://dx.doi.org/10.3390/jcm11030475 |
_version_ | 1784649670080856064 |
---|---|
author | Caso, Valentina Maria Sperlongano, Simona Liccardo, Biagio Romeo, Emanuele Padula, Sergio Arenga, Fortunato D’Andrea, Antonello Caso, Pio Golino, Paolo Nigro, Gerardo Russo, Vincenzo |
author_facet | Caso, Valentina Maria Sperlongano, Simona Liccardo, Biagio Romeo, Emanuele Padula, Sergio Arenga, Fortunato D’Andrea, Antonello Caso, Pio Golino, Paolo Nigro, Gerardo Russo, Vincenzo |
author_sort | Caso, Valentina Maria |
collection | PubMed |
description | PCSK9 inhibitors (PCSK9i) are monoclonal antibodies that have been shown to be effective in reducing both LDL cholesterol (LDL-C) values and major cardiovascular events in patients at high cardiovascular risk. Adherence to PCSK9i is critical for the success of the treatment. The aim of the present study is to evaluate patients’ adherence to PCSK9i during the COVID-19 pandemic. Patients referred to the Cardiac Diagnostic Unit of the University of Campania “Luigi Vanvitelli” Naples, taking PCSK9i, and who missed the cardiological follow-up visit during the first national COVID-19 lockdown (9 March–17 May 2020), were included. Each patient underwent medical teleconsultation to collect current clinical conditions, adherence to drug treatments, and lipid profile laboratory tests. Among 151 eligible patients, 20 were excluded for missing or untraceable telephone numbers and one for refusing to join the interview. The selected study population consisted of 130 patients (64 ± 9 years, 68% males), of whom 11 (8.5%) reported a temporary interruption of the PCSK-9 therapy for a mean period of 65 ± 1.5 days. The non-adherent patients showed a marked increase in LDL-C than in the pre-pandemic period (90.8 ± 6.0 vs. 54.4 ± 7.7 mg/dL, p < 0.0001), and 82% of patients moved out of the LDL-C therapeutic range. The non-adherent group was more likely to have a very high cardiovascular risk compared to the adherent group (81.8 vs. 33.6%, p < 0.001). Causes of interruption included drug prescription failure (63.6%) due to temporary interruption of the non-urgent outpatient visits and failure in drug withdrawal (36.4%) due to patients’ fear of becoming infected during the pandemic. The COVID-19 lockdown caused a remarkable lack of adherence to PCSK9i therapy, risking negative implications for the health status of patients at high cardiovascular risk. Facilitating patients’ access to PCSK9i and enhancing telemedicine seem to be effective strategies to ensure the continuity of care and appropriate management of these patients. |
format | Online Article Text |
id | pubmed-8836402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88364022022-02-12 The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy Caso, Valentina Maria Sperlongano, Simona Liccardo, Biagio Romeo, Emanuele Padula, Sergio Arenga, Fortunato D’Andrea, Antonello Caso, Pio Golino, Paolo Nigro, Gerardo Russo, Vincenzo J Clin Med Article PCSK9 inhibitors (PCSK9i) are monoclonal antibodies that have been shown to be effective in reducing both LDL cholesterol (LDL-C) values and major cardiovascular events in patients at high cardiovascular risk. Adherence to PCSK9i is critical for the success of the treatment. The aim of the present study is to evaluate patients’ adherence to PCSK9i during the COVID-19 pandemic. Patients referred to the Cardiac Diagnostic Unit of the University of Campania “Luigi Vanvitelli” Naples, taking PCSK9i, and who missed the cardiological follow-up visit during the first national COVID-19 lockdown (9 March–17 May 2020), were included. Each patient underwent medical teleconsultation to collect current clinical conditions, adherence to drug treatments, and lipid profile laboratory tests. Among 151 eligible patients, 20 were excluded for missing or untraceable telephone numbers and one for refusing to join the interview. The selected study population consisted of 130 patients (64 ± 9 years, 68% males), of whom 11 (8.5%) reported a temporary interruption of the PCSK-9 therapy for a mean period of 65 ± 1.5 days. The non-adherent patients showed a marked increase in LDL-C than in the pre-pandemic period (90.8 ± 6.0 vs. 54.4 ± 7.7 mg/dL, p < 0.0001), and 82% of patients moved out of the LDL-C therapeutic range. The non-adherent group was more likely to have a very high cardiovascular risk compared to the adherent group (81.8 vs. 33.6%, p < 0.001). Causes of interruption included drug prescription failure (63.6%) due to temporary interruption of the non-urgent outpatient visits and failure in drug withdrawal (36.4%) due to patients’ fear of becoming infected during the pandemic. The COVID-19 lockdown caused a remarkable lack of adherence to PCSK9i therapy, risking negative implications for the health status of patients at high cardiovascular risk. Facilitating patients’ access to PCSK9i and enhancing telemedicine seem to be effective strategies to ensure the continuity of care and appropriate management of these patients. MDPI 2022-01-18 /pmc/articles/PMC8836402/ /pubmed/35159928 http://dx.doi.org/10.3390/jcm11030475 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Caso, Valentina Maria Sperlongano, Simona Liccardo, Biagio Romeo, Emanuele Padula, Sergio Arenga, Fortunato D’Andrea, Antonello Caso, Pio Golino, Paolo Nigro, Gerardo Russo, Vincenzo The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy |
title | The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy |
title_full | The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy |
title_fullStr | The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy |
title_full_unstemmed | The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy |
title_short | The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy |
title_sort | impact of the covid-19 outbreak on patients’ adherence to pcsk9 inhibitors therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836402/ https://www.ncbi.nlm.nih.gov/pubmed/35159928 http://dx.doi.org/10.3390/jcm11030475 |
work_keys_str_mv | AT casovalentinamaria theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT sperlonganosimona theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT liccardobiagio theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT romeoemanuele theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT padulasergio theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT arengafortunato theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT dandreaantonello theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT casopio theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT golinopaolo theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT nigrogerardo theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT russovincenzo theimpactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT casovalentinamaria impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT sperlonganosimona impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT liccardobiagio impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT romeoemanuele impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT padulasergio impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT arengafortunato impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT dandreaantonello impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT casopio impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT golinopaolo impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT nigrogerardo impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy AT russovincenzo impactofthecovid19outbreakonpatientsadherencetopcsk9inhibitorstherapy |